Optiver Holding
SPRY icon

Optiver Holding’s ARS Pharmaceuticals SPRY Stock Holding History

Optiver Holding’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12K Sell
140
-184
-57% -$1.58K ﹤0.01% 2464
2026
Q1 		$2.6K Buy
324
+64
+25% +$613 ﹤0.01% 1742
2025
Q4 		$3.03K Sell
260
-96
-27% -$934 ﹤0.01% 1746
2025
Q3 		$3.58K Buy
+356
New +$5.11K ﹤0.01% 2055

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Optiver Holding's SPRY Position: Q2 2026 in Review

Optiver Holding reduced its ARS Pharmaceuticals (SPRY) stake by 57% in Q2 2026, selling an estimated $1.58K and leaving 140 shares worth $1.12K. The position accounts for ﹤0.01% of the portfolio, ranked #2464.

Optiver Holding first reported a position in SPRY in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.58K in Q3 2025. 208 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Optiver Holding held 140 shares of ARS Pharmaceuticals worth $1.12K as of Q2 2026.
  • Optiver Holding sold 184 ARS Pharmaceuticals shares in Q2 2026, an estimated $1.58K.
  • ARS Pharmaceuticals made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2464 holding.
  • Optiver Holding first reported a position in ARS Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's ARS Pharmaceuticals position peaked at $3.58K in Q3 2025.
  • 208 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.